These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12888936)

  • 1. Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer.
    Wojtukiewicz MZ; Sierko E; Zacharski LR; Rózanska-Kudelska M; Zimnoch L
    Semin Thromb Hemost; 2003 Jun; 29(3):317-20. PubMed ID: 12888936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The location of components of fibrinolytic system in laryngeal cancer].
    Sierko E; Tokajuk P; Zimnoch L; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2003 Jul; 15(85):81-5. PubMed ID: 14593967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fibrinolytic system in neoplasia.
    Bell WR
    Semin Thromb Hemost; 1996; 22(6):459-78. PubMed ID: 9122711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma.
    Wojtukiewicz MZ; Zacharski LR; Ruciñska M; Zimnoch L; Jaromin J; Rózañska-Kudelska M; Kisiel W; Kudryk BJ
    Thromb Haemost; 1999 Dec; 82(6):1659-62. PubMed ID: 10613652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
    Costantini V; Zacharski LR; Memoli VA; Kudryk BJ; Rousseau SM; Stump DC
    Cancer Res; 1991 Jan; 51(1):354-8. PubMed ID: 1846311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
    Paciucci R; Torà M; Díaz VM; Real FX
    Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
    Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
    Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of blood coagulation factors in situ in pancreatic carcinoma.
    Wojtukiewicz MZ; Rucinska M; Zacharski LR; Kozlowski L; Zimnoch L; Piotrowski Z; Kudryk BJ; Kisiel W
    Thromb Haemost; 2001 Dec; 86(6):1416-20. PubMed ID: 11776308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen-fibrin transformation in situ in renal cell carcinoma.
    Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
    Anticancer Res; 1990; 10(3):579-82. PubMed ID: 2114816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva.
    Parolini S; Rosa D; Flagiello D; Bonardi F; Rampinelli F; Bianchi UA; Molinari Tosatti MP
    Int J Tissue React; 1994; 16(5-6):251-8. PubMed ID: 7558669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
    Zacharski LR; Memoli VA; Ornstein DL; Rousseau SM; Kisiel W; Kudryk BJ
    J Natl Cancer Inst; 1993 Aug; 85(15):1225-30. PubMed ID: 8331683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathways of coagulation/fibrinolysis activation in malignancy.
    Zacharski LR; Wojtukiewicz MZ; Costantini V; Ornstein DL; Memoli VA
    Semin Thromb Hemost; 1992 Jan; 18(1):104-16. PubMed ID: 1574711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients.
    Zhao W; Wang X; Qu B; Huang X; Wang H
    Chin Med J (Engl); 2002 May; 115(5):702-4. PubMed ID: 12133538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
    Sirén V; Peltonen J; Vaheri A
    Arch Dermatol Res; 2006 Mar; 297(9):421-4. PubMed ID: 16408192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer.
    Wojtukiewicz MZ; Sierko E; Zacharski LR; Zimnoch L; Kudryk B; Kisiel W
    Semin Thromb Hemost; 2003 Jun; 29(3):291-300. PubMed ID: 12888933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
    Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
    Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.